14 Apr 2026 by admin in UncategorizedComments Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
07 Apr 2026 by admin in UncategorizedComments NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
27 Mar 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Pricing of Concurent Public Oferings of 2.50% Convertible Senior Notes Due 2032 and Comon Stock with Agregate Gros Proceds of $30.0 Milion Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
23 Mar 2026 by admin in UncategorizedComments Tempest Therapeutics Announces Up To $6 Million Private Placement
11 Mar 2026 by admin in UncategorizedComments Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
23 Feb 2026 by admin in UncategorizedComments Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
11 Feb 2026 by admin in UncategorizedComments Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
09 Feb 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Late-Breaking Platform Presentation of Results from Phase 2 MonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
